食管癌手术患者的生存率及其影响因素分析

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (584 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the survival of patients with esophageal cancer.Methods Fifty-four patients with esophageal cancer were selected between May 2012 and January 2018 in Lishui People’s Hospital. Patients were reexamined every 3 to 6 months in the first year, followed by follow-ups every 6 to 12 months, and routine chest and abdominal CT was performed. Related information on surgery of esophageal cancer was retrieved from the department of medical records, electronic medical records were consulted from the HIS system to find out about the re-hospitalization of these patients, and the patients were followed up on the telephone asking about the therapeutic effect and survival. The follow-up deadline was January 31, 2018. The median duration of follow-up was 20 months. One case was later out of touch and the follow-up rate was 98.8%.Results The 1-year, 3-year and 5-year recurrence-free survival rates of these 54 patients were 66.1%, 58.1% and 58.1%, respectively. The overall survival rates were 83.4%, 61.8% and 61.8% respectively. The overall survival rate of esophageal cancer was related to age (OR 3.848, 95% CI 1.047-14.143)and lymph node metastasis(OR 4.777, 95% CI 1.165-19.594), but not to chemotherapy.Conclusions Total postoperative survival rate in patients with esophageal cancer is related to age and lymph node metastasis. Postoperative adjuvant chemotherapy fails to show any significant advantage.

Key words： esophageal cancer adjuvant chemotherapy overall survival rate

Received: 20 June 2018

ZTFLH:

R735.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Feng
	SUN Baolin
	YU Shouqiang
	QUAN Yonghui
	ZHOU Zhiliang
	WANG Yong
	HU Mingwei
	WU Kunpeng
	ZHU Jun.

Cite this article:

LIU Feng,SUN Baolin,YU Shouqiang等. Survival analysis of patients with esophageal cancer[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(11): 1044-1046.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2018/V29/I11/1044

[1]	Pennathur A, Gibson M K, Jobe B A,et al. Oesophageal carcinoma [J]. Lancet,2013,381 (9864): 400-412.
[2]	Shridhar R, Hayman T, Hoffe S E, et al. Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy[J]. J Gastrointest Surg, 2012,16(7): 1296-1302.
[3]	李续源, 罗向三, 王鸿彪, 等. 胸段食管鳞癌手术治疗或根治性放化疗的复发和生存分析[J]. 肿瘤防治研究,2017,44(4): 286-289.
[4]	Kelvin K, Chan W, Saluja R, et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis [J]. Int J Cancer, 2018, 143(2): 430-437.
[5]	Van Hagen P, Hulshof M C, Van Lanschot J, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22): 2074-2084.
[6]	Almhanna K, Shridhar R, Meredith K L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care? [J]. Cancer Control, 2013, 20(2): 89-96.
[7]	Ychou M, Boige V, Pignon J P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial [J]. J Clin Oncol, 2011, 29 (13): 1715-1721.
[8]	Cunningham D, Allum W H, Stenning S P, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1):11-20.
[9]	Tam V, Hooker C M, Molena D, et al. Clinical response to neoadjuvant therapy to predict success of adjuvant chemotherapy for esophageal adenocarcinoma[J]. J Clin Oncol, 2014,32: 137.
[10]	Saeed N A, Mellon E A, Meredith K L,et al. Adjuvant chemotherapy and outcomes in esophageal carcinoma[J]. J Gastroint Oncol, 2017, 8(5): 816-824.
[11]	彭进, 何栋成, 姚蓉,等. 同步放化疗治疗食管癌术后复发的临床效果及预后因素分析[J]. 现代肿瘤医学,2015, 23(17):2442-2445.
[12]	Guo Xufeng, Mao Teng, Gu Zhitao, et al. Clinical study on postoperative recurrence in patients with pN1 esophageal squamous cell carcinoma[J]. Thoracic Cancer, 2015, 6(2):146-150.
[13]	Pasquer A, Gronnier C, Renaud F, et al. Impact of adjuvant chemotherapy on patients with lymph node-positive esophageal cancer who are primarily treated with surgery [J]. Ann Surg Oncol, 2015, 22 (Suppl 3): S1340-1349.
[14]	孙志伟,贾军,杨颖, 等. 晚期食管癌患者营养状态与化疗疗效及生存的相关性[J]. 肿瘤防治研究, 2017, 44(9):612-617.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(8): 718-719.